Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Geron is a biopharmaceutical company focused on developing therapeutic and diagnostic products for cancer based on telomerase technology and cell-based therapeutics using human embryonic stem cell (hESC) technology. The company has no approved products on the market and relies on collaborative agreements and license fees for revenue.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2004 |
Six Months Ended June 30, 2004 |
Six Months Ended June 30, 2003 |
|---|---|---|---|
| Total Revenues | $366 | $614 | $547 |
| Net Loss | $(8,945) | $(60,628) | $(17,220) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(1.41) | $(0.63) |
| Research & Development Expenses | $7,481 | $13,199 | $14,523 |
| General & Administrative Expenses | $2,053 | $3,444 | $2,721 |
| Acquired In-Process R&D Expense | $0 | $45,150 | $0 |
| Cash and Cash Equivalents | $8,026 | $8,026 | $10,956 |
| Marketable Securities | $85,920 | $85,920 | $N/A |
| Total Current Assets | $103,834 | $103,834 | $N/A |
| Total Current Liabilities | $9,081 | $9,081 | $N/A |
| Accumulated Deficit | $(316,294) | $(316,294) | $(255,666) |
Liquidity: As of June 30, 2004, the company held approximately $94.5 million in cash, restricted cash, cash equivalents, and marketable securities. Management estimates these resources are sufficient to fund operations through June 30, 2006.
Material Changes vs. Prior Period
- Revenue: Total revenues for the six months ended June 30, 2004, increased to $614,000 from $547,000 in the prior year period. This increase was driven by higher license fee revenues ($560,000 vs. $380,000) due to new agreements signed in Q2 2004. Revenues from collaborative agreements were $0 for the current period compared to $72,000 in the prior year.
- Net Loss: Net loss for the six months ended June 30, 2004, increased significantly to $60.6 million from $17.2 million in the prior year. This increase was primarily due to a one-time non-cash charge of $45.2 million for acquired in-process research technology (IPR&D) related to the Merix Bioscience, Inc. transaction.
- Operating Expenses: R&D expenses decreased slightly to $13.2 million from $14.5 million year-over-year, attributed to lower manufacturing costs and personnel costs. G&A expenses increased to $3.4 million from $2.7 million, driven by higher legal and accounting fees related to litigation and stock issuances.
- Cash Flow: Net cash used in operating activities was $13.6 million, a slight decrease from $13.8 million in the prior year. Net cash provided by investing activities was $7.7 million, largely due to proceeds from the sale of marketable securities and equity investments.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to recognize approximately $81,000 in revenue from existing deferred revenue for the remainder of 2004.
- R&D expenses are expected to increase in the next year due to manufacturing and testing of telomerase inhibitor compounds, clinical trials for the telomerase cancer vaccine, and hESC program development.
- Management anticipates needing substantial additional capital to fund operations beyond mid-2006.
Management Commentary:
- Merix Acquisition: In March 2004, Geron acquired co-exclusive rights to Merix Bioscience's cancer vaccine technology, issuing 5 million shares of common stock. The $45.2 million value was expensed immediately as the technology had no alternative future use.
- Kyowa Hakko Termination: In June 2004, Geron terminated its agreement with Kyowa Hakko, regaining worldwide rights to telomerase inhibitors.
- Kirin Litigation: A lawsuit filed by Kirin Brewery Co., Ltd. regarding the Merix acquisition was settled in June 2004 with no payment or transfer of IP rights.
Risks and Contingencies:
- Regulatory Approval: No products are currently approved. Success depends on obtaining FDA and international regulatory approvals, which are uncertain and costly.
- Capital Requirements: The company has a history of losses and expects to continue incurring losses. Failure to secure additional funding could force delays or elimination of programs.
- Intellectual Property: The company faces ongoing patent interferences and oppositions, particularly regarding nuclear transfer and telomerase technologies.
- Stem Cell Ethics: Political and religious opposition to human embryonic stem cell research could restrict funding or commercialization.
Key Facts for Investor Verification
- One-Time Expense Impact: Verify the impact of the $45.2 million non-cash charge for the Merix IPR&D acquisition on the reported net loss for the six months ended June 30, 2004.
- Cash Runway: Confirm the company's estimate that current capital resources ($94.5 million) are sufficient to fund operations only through June 30, 2006, necessitating future financing.
- Revenue Composition: Note that revenue is currently derived almost entirely from license fees and royalties, with no product sales from therapeutic candidates.
- Legal Resolution: Confirm the dismissal of the Kirin Brewery lawsuit and the lack of financial impact from the settlement.
- Stock Issuances: Review the issuance of 5 million shares to Merix and other stock issuances for services/supplies, which may impact dilution.